YOLFTbeta
Kura Oncology Inc

Kura Oncology Inc

KURA · NASDAQ · Healthcare / Biotechnology

7.77USD+0.34 (+4.58%)

Price History

Full chart

Market Stats

Previous Close7.43
Open7.50
Day Range7.30 – 7.82
52-Week Range7.36 – 13.90
Volume2.23M
Market Cap957.22M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.32
Dividend Yield0.00%
Beta0.43
50-Day Avg11.18
200-Day Avg9.81

About

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Troy Edward Wilson J.D., Ph.D.
  • Employees260
  • Headquarters4930 Directors Place, San Diego, CA, United States, 92121, USA
  • Websitehttps://kuraoncology.com

Leadership

  • Dr. Troy Edward Wilson J.D., Ph.D.Chairman, CEO & President · b. 1969
  • Ms. Kathleen FordChief Operating Officer · b. 1947
  • Mr. Brian T. Powl M.B.A., M.S.Chief Commercial Officer · b. 1974
  • Mr. Thomas DoyleSenior Vice President of Finance & Accounting · b. 1971
  • Dr. Francis J. Burrows Ph.D.Chief Scientific Officer · b. 1962
  • Mr. Greg MannSenior Vice President of Investor Relations & Corporate Affairs
  • Ms. Teresa Brophy Bair Esq., J.D.Chief Legal Officer & Corporate Secretary · b. 1971
  • Dr. Roger Bakale Ph.D.Senior Vice President of Manufacturing & Supply Chain
  • Dr. Mollie Leoni M.D.Chief Medical Officer · b. 1978
  • Mr. Samir Vattompadam M.S.Senior Vice President of Global Program Leadership

Financials

Income Statement

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue------000000000053.88M67.48M
Growth (%)-----------------+25.24%
Cost of Revenue-19.16K20.51K23.44K22.34K22.73K23.91K20.00K31.00K30.00K10.00K-194.00K558.00K759.00K849.00K848.00K57.00K
Gross Profit--19.16K-20.51K-23.44K-22.34K-22.73K-23.91K-20.00K-31.00K-30.00K-10.00K--194.00K-558.00K-759.00K-849.00K53.88M67.42M
Gross Margin----------------100.00%99.92%
Operating Expense-19.16K20.51K-2.93K1.10K-39311.78M23.84M28.34M36.05M62.87M-91.70M130.70M139.11M164.96M247.08M371.06M
Operating Income-33.62K-38.32K-41.02K-20.51K-23.44K-22.34K-11.80M-23.86M-28.37M-36.08M-62.88M-67.48M-91.90M-131.26M-139.87M-165.80M-193.19M-303.63M
Operating Margin-----------------358.55%-449.94%
EBITDA-33.62K-38.32K-41.02K-20.51K-23.44K-22.34K-11.80M-23.84M-28.34M-36.05M-62.87M-67.48M-88.85M-129.49M-134.85M-150.23M-169.50M-275.82M
EBITDA Margin-----------------314.57%-408.74%
Net Income-33.62K-20.00K-22.39K-22.39K-27.04K-27.32K-11.01M-22.63M-27.56M-35.43M-60.45M-63.14M-89.63M-130.47M-135.84M-152.63M-173.98M-278.67M
Net Income Margin-----------------322.89%-412.95%
R&D------8.05M17.78M20.40M26.43M46.79M47.83M60.40M84.72M92.81M115.23M169.97M251.07M
R&D as % of Total Revenue----------------315.44%372.06%
Interest Expense-8381.89K1.89K3.60K4.97K5.88K88.00K577.00K888.00K970.00K580.00K578.00K414.00K229.00K1.55M1.62M1.51M
Interest Expense % of Total Revenue----------------3.00%2.24%

Balance Sheet

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.51K13.02K29.40K6.72K8.30K9.07K1.38M87.26M69.82M95.85M182.38M241.97M647.21M534.05M456.31M448.94M760.16M738.36M
Total Liabilities-31.61K70.39K74.75K103.65K133.03K4.81M5.16M12.95M15.99M21.39M23.19M36.31M27.44M36.03M51.66M346.52M564.23M
Total Equity1.40K-18.60K-40.99K-68.03K-95.35K-123.96K-3.43M82.10M56.88M79.86M160.99M218.78M610.90M506.61M420.28M397.27M413.64M174.13M
Cash7.51K11.14K26.90K4.22K4.80K6.57K1.12M15.44M9.72M11.43M16.12M26.14M325.49M90.67M51.80M37.32M224.46M149.10M
Total Debt-25.00K60.00K120.00K170.00K220.00K2.53M-7.32M7.10M7.50M7.75M14.98M6.88M14.02M17.20M16.59M20.46M
Net Debt-7.51K13.86K33.10K115.78K165.20K213.43K1.41M-15.44M-2.40M-4.33M-8.62M-18.38M-310.52M-83.80M-37.78M-20.12M-207.87M-128.64M

Cash Flow

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-31.77K-21.37K-19.24K-19.24K-22.68K-24.42K-2.55K-17.93M-25.35M-28.44M-48.66M-54.76M-69.83M-104.55M-110.06M-124.82M134.32M-64.06M
Investing Cash Flow-------84-70.63M12.18M-23.42M-79.30M-46.33M-99.94M-126.83M32.63M15.56M-101.59M-13.10M
Financing Cash Flow-25.00K35.00K35.00K25.00K25.00K6.00K102.87M7.45M53.57M132.64M111.10M469.33M-3.44M38.56M94.78M154.42M1.79M
Capital Expenditure0000008464.00K02.17M2.17M2.17M2.17M1.15M626.00K168.00K472.00K6.64M
Free Cash Flow-31.77K-21.37K-19.24K-19.24K-22.68K-24.42K-2.63K-17.99M-25.35M-28.44M-48.66M-54.76M-72.00M-105.70M-110.69M-124.99M133.84M-70.70M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%103.30%100.36%100.00%100.00%100.00%100.00%103.11%101.10%100.57%100.13%99.65%110.36%

Earnings

Report DateNov 13, 2015Mar 17, 2016May 11, 2016Aug 10, 2016Nov 7, 2016Mar 14, 2017May 15, 2017Aug 7, 2017Nov 7, 2017Mar 12, 2018May 8, 2018Aug 6, 2018Nov 5, 2018Mar 5, 2019May 7, 2019Aug 1, 2019Nov 5, 2019Feb 25, 2020May 4, 2020Aug 6, 2020Nov 5, 2020Feb 24, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Feb 24, 2022May 4, 2022Aug 3, 2022Nov 3, 2022Feb 23, 2023May 10, 2023Aug 3, 2023Nov 2, 2023Feb 27, 2024May 2, 2024Aug 8, 2024Nov 7, 2024Feb 25, 2025May 1, 2025Aug 7, 2025Nov 4, 2025Mar 5, 2026Apr 30, 2026Aug 12, 2026Nov 3, 2026
EPS Estimate-0.42-0.48-0.38-0.39-0.39-0.40-0.42-0.43-0.38-0.36-0.35-0.43-0.43-0.42-0.44-0.41-0.39-0.41-0.42-0.43-0.40-0.45-0.42-0.50-0.54-0.53-0.52-0.52-0.56-0.57-0.54-0.56-0.55-0.55-0.54-0.62-0.61-0.64-0.600.15-0.68-0.49-0.90-0.89-0.84
EPS Actual-0.57-0.42-0.36-0.36-0.37-0.38-0.39-0.40-0.38-0.37-0.46-0.45-0.40-0.42-0.37-0.38-0.36-0.39-0.42-0.40-0.42-0.45-0.46-0.51-0.50-0.49-0.49-0.52-0.53-0.49-0.50-0.53-0.50-0.55-0.59-0.59-0.63-0.22-0.66-0.75-0.85-0.92-0.83-0.77-
Surprise-35.71%12.50%5.26%7.69%5.13%5.00%7.14%6.98%0.00%-2.78%-31.43%-4.65%6.98%0.00%15.91%7.32%7.69%4.88%0.00%6.98%-5.00%0.00%-9.52%-2.00%7.41%7.55%5.77%0.00%5.36%14.04%7.41%5.36%9.09%0.00%-9.26%4.84%-3.28%65.49%-10.00%-600.00%-25.00%-87.76%8.35%13.48%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-market-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap957.22M
Enterprise Value486.67M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales12.40
Price / Book20.26
EPS-3.32
Book Value0.544
Revenue (TTM)77.22M
Gross Profit (TTM)-182.81M
EBITDA-316.80M
Profit Margin0.00%
Operating Margin-349.77%
Return on Equity-167.71%
Return on Assets-31.30%
Shares Outstanding88.96M
Shares Float70.44M
Beta0.43
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 15 analystsTarget 32.00
  • Strong Buy
    10
  • Buy
    3
  • Hold
    2

Ownership Breakdown

Institutions
99.77%
Insiders
1.39%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    9.64M10.83%
  • Suvretta Capital Management, LLC
    8.58M9.64%
  • Bvf Inc
    8.45M9.49%
  • State Street Corp
    4.51M5.07%
  • Vanguard Capital Management, LLC
    3.79M4.26%
  • Armistice Capital, LLC
    3.74M4.20%
  • AQR Capital Management LLC
    2.12M2.39%
  • Geode Capital Management, LLC
    2.03M2.29%
  • Prosight Management, LP
    2.02M2.27%
  • Deep Track Capital, LP
    1.98M2.22%
  • Qube Research & Technologies
    1.64M1.84%
  • Renaissance Technologies Corp
    1.58M1.78%
  • Alethea Capital Management, LLC
    1.53M1.72%
  • The Goldman Sachs Group Inc
    1.43M1.61%
  • Vanguard Portfolio Management, LLC
    1.23M1.38%
  • Bank of America Corp
    1.23M1.38%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    3.25M3.65%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.80M3.15%
  • iShares Russell 2000 ETF
    2.18M2.45%
  • HBM Healthcare Investments AG Ord
    1.79M2.01%